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ABSTRACT
Bevacizumab plus weekly paclitaxel improves progression-free survival (PFS) 
in HER2-negative metastatic breast cancer (mBC), but its use has been questioned 
due to the absence of a predictive biomarker, lack of benefit in overall survival (OS) 
and increased toxicity. We examined the baseline tumor angiogenic-related gene 
expression of 60 patients with mBC with the aim of finding a signature that predicts 
benefit from this drug.
Multivariate analysis by Lasso-penalized Cox regression generated two predictive 
models: one, named G-model, including 11 genes, and the other one, named GC-
model, including 13 genes plus 5 clinical covariates. Both models identified patients 
with improved PFS (HR (Hazard Ratio) 2.57 and 4.04, respectively) and OS (HR 3.29 
and 3.43, respectively). The G-model distinguished low and high risk patients in the 
first 6 months, whereas the GC-model maintained significance over time.
INTRODUCTION
Breast cancer is a heterogeneous disease regarding 
molecular and clinical features. In the metastatic setting, 
the expression of human epidermal growth factor receptor 
2 (HER2) and hormonal receptors determine the selection 
of therapies. Treatment for HER-2 negative mBC includes 
hormonal therapy, chemotherapy and bevacizumab 
combined regimens.
In the pivotal E2100 study, bevacizumab plus 
weekly paclitaxel increased overall response rate (50% vs 
22%) and progression-free survival (PFS) (median of 11.8 
vs 5.9 months) compared to paclitaxel alone [1]. Other 
phase III trials in mBC also reported a PFS benefit with 
the addition of bevacizumab to chemotherapy, both in 
first [2, 3] and second line therapies [4]. However, none 
of them showed a significant improvement in overall 
survival (OS), possibly due to the confounding effect 
of post-progression therapy, lack of statistical power, or 
treatment crossover. This, along with economic issues, 
lack of validated biomarkers and increased toxicity has put 
into question the role of bevacizumab in mBC. Nowadays, 
the identification of predictive biomarkers for this drug 
remains a challenge.
Technological improvements in molecular profiling 
have allowed a better knowledge of breast cancer biology, 
leading to the development of new tests that help in 
clinical decision making.
In the present study we analysed a set of 168 genes 
related to angiogenesis and other processes on a discrete 
series of patients treated with bevacizumab and weekly 
paclitaxel. Our aim was to find a molecular signature 
predicting PFS benefit from this regimen. To date, this is 
the first report of a biomarker profile with PFS prediction. 
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We selected genes implicated in angiogenesis and other 
related processes, such as Epithelial to Mesenchymal 
Transition (EMT) and inflammation, that could have an 
impact in the response or resistance to bevacizumab [5].
RESULTS
Descriptive statistics and univariate analysis
Sixty patients were included and their clinical 
characteristics are summarized in Table 1. Median age at 
diagnosis was 54 years (range 33-76). Almost half of the 
patients had received prior therapy with anthracyclines 
and taxanes, and 40% had been treated with one or more 
previous lines of chemotherapy for metastatic disease.
Forty-five percent of the patients achieved a 
partial response and 13% a complete response. Median 
PFS was 11.4 months (range 0.5-46.1), and median OS 
was 29 months (range 1.41-44.8). All patients received 
bevacizumab until progression, but paclitaxel had to be 
discontinued after 6-8 cycles in 32 patients, mostly due to 
toxicity. During the bevacizumab continuation phase, 15 
patients (53.5% of estrogen receptor -ER- positive patients 
with continuation treatment) also received hormonal 
therapy.
Table 1: Patients characteristics
Patients characteristics N (%)
Estrogen Receptor (ER)  
 Positive 49 (81.7)
 Negative 11 (18.3)
Progesterone receptor (PR)  
 Positive 41 (68.3)
 Negative 19 (31.7)
IHQ subtype  
 Triple negative 11 (18.3)
 ER positive, PR negative 8 (13.3)
 ER positive, PR positive 41 (68.3)
Adjuvant chemotherapy  
 Yes 46 (76.7)
 No 14 (23.3)
Disease-free interval  
 ≤ 24 months 17 (28.3)
 > 24 months or stage IV at diagnosis 43 (71.7)
Number of chemo lines for metastasic disease  
 0 36 (60)
 >1 24 (40)
Previous chemotherapy  
 None (or non antracyclines: e.g. CMF) 15 (25)
 Anthracyclines 17 (28.3)
 Anthracyclines and taxanes 28 (46.7)
Metastatic locations  
 1 or 2 27 (45)
 ≥ 3 or hepatic involvement 33 (55)
IHQ: inmunohistochemistry CMF: old chemotherapy regimen
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Univariate analysis of clinical and pathological 
variables for PFS is presented in Table 2. Disease-free 
interval (DFI), ER and metastatic location (3 or more 
locations or hepatic involvement) were significantly 
associated with PFS. Summary information for the gene 
expression measurements as well as the Hazard Ratio 
(HR) for the association between the gene expression 
values and PFS is presented on Supplementary Table. Nine 
genes (CDH11, ESR1, FABP5, FN1, IL8, NOTCH3, PGR, 
PLAU and SLC39A6) showed adjusted p values <0.05 for 
association with cancer progression.
Multivariate cox models
A multivariate analysis with five clinical variables 
(DFI, ER, ML, prior anthracyclines and taxanes, and 
prior chemotherapy treatment for metastatic disease) was 
associated with PFS (Table 3). This was defined as the 
clinical or C-model.
We then combined clinical and gene variables 
into two models using the least absolute shrinkage and 
selection operator (LASSO) [6] [7] for variable selection: 
one model had gene expression only (G-model), and the 
other had both gene expression and clinical variables (GC-
model). The G-model included 11 genes (SLC39A6, REL, 
IL8, FN1, PLAU, HES1, HMBS, DDIT4, FABP5, ACVRL1, 
PGR) (Table 4). The GC-model consists of 13 genes (REL, 
FN1, NOTCH3, DDIT4, IL8, ADRBK1, FABP5, PLAU, 
HMBS, PTK2B, THBS1, SLC39A6, TCF3) and the five 
clinical variables mentioned previously (Table 5). The beta 
coefficient signs of the genes agreed with the expression 
results from the univariate analysis. Figure 1 shows 
Kaplan Meier plots for progression-free survival (PFS) 
and overall survival (OS) in G and GC models. The HR, 
differences in median and p values for these predictions 
are summarized in Tables 6 (PFS) and 7(OS).
Comparison of accuracy of prediction of the 
models through roc curves
Models were also compared to evaluate the gain of 
accuracy by time-dependent ROC curves [8], and results 
are shown in Figure 2. In the first 6 months G and GC 
models worked better than C model (AUC 0.68 and 
0.72 versus AUC 0.53 respectively). The G model lose 
accuracy with longer follow-up, whereas GC remained 
accurate over time, as shown in Figures 2c and 2d.
Inmunohistochemistry evaluation of biomarkers
Tissue microarrays (TMA) were used to evaluate the 
protein expression encoded by those genes with the higher 
beta coefficients: cREL, SLC39A6, NOTCH, FN1 and 
DDIT4. A summary of these studies is shown in Figure 
3. None of the proteins analyzed were independently 
associated with PFS.
DISCUSSION
Bevacizumab was approved as first-line treatment 
for mBC in 2008. Three years later, the Food and Drug 
Administration revoked the indication due to increased 
Table 2: Univariate analysis of clinical variables for progression-free survival
Variable HR (95% CI) P value
Age 1.02 (0.99-1.04) 0.18
Disease-free interval
(≥24 vs < 24 months)
0.49 (0.27-0.89) 0.02
Estrogen-receptor
(positive vs negative) 0.42 (0.21-0.83) 0.02
Progesterone-receptor
(positive vs negative) 0.58 (0.32-1.03) 0.07
Adjuvant chemotherapy
(yes vs no) 0.69 (0.37-1.27) 0.25
Prior anthracyclines and taxanes (yes vs no) 1.17 (0.63-2.17) 0.62
Prior lines for metastatic disease (≥ 1 vs 0) 1.64 (0.93-2.87) 0.09
Metastatic location
(< 3 locations and no liver involvement vs 
≥ 3 or hepatic)
2.92 (1.61-5.32) 0.0003
Hormonal therapy* 0.48 (0.2-1.17) 0.11
*Only in subgroup of patients with bevacizumab continuation treatment and ER positive
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toxicity without a clear benefit in OS. However, the 
European Medicines Agency decided to keep the 
indication, but only in combination with paclitaxel 
(regimen with the most benefit in SLP).
The identification of a reliable biomarker would 
avoid unnecessary toxicity in non-responders, reduce 
healthcare costs, and therefore improve cost-effectiveness. 
VEGF is a master regulator of angiogenesis, and should 
be expected to predict response to bevacizumab, but the 
results of different studies are controversial. Translational 
studies associated to bevacizumab trials in mBC have 
shown a possible role of plasmatic VEGFA (pVEGFA) and 
VEGFR2 levels as response predictors [9-12]. However, 
preliminary results of the prospective study Meridian 
showed that baseline pVEGFA levels were not associated 
to improved PFS [13].
Due to the high number of genes involved in 
angiogenesis, a single biomarker is unlikely to predict 
benefit from bevacizumab. Therefore, identification of 
alternative biomarkers is a main subject for translational 
oncology research, and, to our knowlegde, this is the 
first report of a biomarker profile predicting PFS benefit 
in mBC patients treated with bevacizumab and weekly 
paclitaxel.
We selected a group of genes described to have 
a role in angiogenesis and other related processes, to 
investigate if any combination could impact on response 
to bevacizumab [5]. In the multivariate analysis we 
decided to include clinical factors found to be relevant 
in another study with bevacizumab-containing therapy 
[14]. Some of these factors did not reach statistical 
significance, probably due to the small sample size. 
Table 3: Clinical multivariate analysis for progression-free survival (C-model)
Variable HR (CI 95%) P value
Disease-free interval
(≥24 vs < 24 months)
0.74 (0.35-1.59) 0.43
Estrogen-receptor
(positive vs negative) 0.41 (0.17-1.03) 0.06
Prior anthracyclines and taxanes
(yes vs no) 1.02 (0.52-2.01) 0.94
Prior lines for metastatic disease
(≥ 1 vs 0)
1.55 (0.8-3) 0.19
Metastatic location
(< 3 locations and no liver involvement 
vs ≥ 3 or hepatic)
3.07 (1.63-5.8) 0.0005
Table 4: Genetic model (G-model)
Gene Beta coefficient (LASSO) HR (IC95%)
SLC39A6 0,289 1,72 (1,28-2,3)
REL -0,282 0,74 (0,56-0,99)
IL8 -0,231 0,7 (0,54-0,89)
FN1 0,191 1,51 (1,18-1,93)
PLAU 0,152 1,5 (1,14-1,98)
HES1 0,138 1,15 (0,92-1,44)
HMBS -0,063 0,81 (0,64-1,04)
DDIT4 0,049 1,14 (0,87-1,51)
FABP5 -0,043 0,72 (0,55-0,96)
ACVRL1 0,031 1,32 (0,99-1,77)
PGR 0,021 1,46 (1,09-1,95)
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This is the main weakness of our study, along with the 
absence of a validation set. Validation was not feasible 
because of the limited number of patients treated with 
bevacizumab and paclitaxel. Possible biases are difficult 
to be controlled in a retrospective study, including the 
use of chemotherapy before bevacizumab and the use of 
hormonal therapy during the bevacizumab continuation 
phase in some patients. The latter group was not included 
in the multivariate analysis.
On the other hand, the strengths of our work are 
the biological plausibility of the selected genes, the low 
number of genes included in the models, and the statistical 
method that offers a robust internal validation.
The G-model consists of 11 genes, and the GC-
model includes 5 clinical covariates and 13 genes. Among 
the genes, 8 are present in both models: SLC39A6, 
REL, IL8; FN1, PLAU, HES1, HMBS, DDIT4, FABP5, 
ACVRL1, and PGR. The sign of beta coefficients agrees 
in all cases with the expression results of the univariate 
analysis of the genes, and is maintained in both models. 
SLC39A6 and REL in the G-model, and FN1 and, again, 
REL in the GC-model had the highest weight.
SLC39A6 expression has been described in clinical 
breast-tumour populations as significantly associated 
with the estrogen receptor status [15]. It has also been 
associated with the spread of breast cancer to regional 
lymph nodes [16, 17]. Interestingly, this gene had the 
highest beta coefficient in the G-model, but one of the 
lowest in the GC one, where ER is also included.
FN1 has been previously described as part of an 
extracellular matrix gene cluster associated with resistance 
to first-line tamoxifen therapy in patients with mBC and 
with the development of metastasis [18] [19].
REL is part of the nuclear factor-κappaB (NF-κB) 
complexes. It had the highest beta coefficient in both 
models, being associated with improved PFS and OS. 
The involvement of NF-κB in neoplastic proliferation 
of human breast cancer cells has been described under 
estrogen-free conditions in vitro, where it induces additive 
anticancer effects with tamoxifen [20]. Its specific role 
Table 5: Combined genetic and clinical model (GC-model)
Variable Beta (LASSO) HR
Disease-free interval
(≥24 vs < 24 months)
-0.223 0.8
Estrogen-receptor
(positive vs negative) -0.907 0.4
Prior anthracyclines and taxanes (yes vs 
no) 0.008 1.014
Prior lines for metastatic disease (≥ 1 vs 
0) 0.45 1.57
Metastatic location
(< 3 locations and no liver involvement 
vs ≥ 3 or hepatic)
1.509 4.52
REL -0.349 0.71
FN1 0.322 1.38
NOTCH3 0.287 1.33
DDIT4 0.281 1.32
IL8 -0.223 0.8
ADRBK1 -0.21 0.81
FABP5 -0.176 0.84
PLAU 0.159 1.17
HMBS -0.155 0.86
PTK2B 0.136 1.15
THBS1 0.114 1.12
SLC39A6 0.05 1.05
TCF3 -0.028 0.97
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in antiangiogenic therapy response should be further 
characterized.
We used LASSO Cox regression model to determine 
genes significantly related to PFS. This model accounts 
for overfitting, a problem inherent to studies where the 
number of genes far exceeds the number of patients. The 
output is a profile with a reduced number of genes, which 
makes it more suitable for clinical application. We also 
used LOOCV method, and a permutation test to assess 
the statistical significance of the models. Both GC and G 
models fared better than C model, being correlated with 
PFS and OS (Table 7).
We also tested the predictive accuracy of these 
models by time-dependent ROC curves (Figure 2). 
The relative weight of the gene component in G and 
GC models remained constant over time, whereas the 
clinical variables were important in the long term. A 
plausible explanation is that clinical parameters are purely 
prognostic, whereas genes predict benefit from treatment, 
so their influence is detected earlier.
In summary, we described two models that predict 
improved PFS and OS with bevacizumab-paclitaxel 
therapy: the G-model included a combination of 11 genes, 
and the (GC-model consisted of 13 genes and 5 clinical 
Figure 1: Progression-free survival and overall survival Kaplan-Meier curves of the two groups established by the 
G-model (a and b) and by the GC-model (c and d).
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Table 6: Hazard ratio, medians of progression-free survival and p-values of the two groups of patients established by 
the G and GC models
Model Risk Group HR (CI 95%) p-value Median PFS 
(months)
G-model
Low-risk 1
0,048
16,9 (12,3-25,8)
High-risk 2.57 (1.47-4.48) 7,4 (5,7-12,4)
GC-model
Low-risk 1
<0,001
17,9 (13,7-29,8)
High-risk 4.04 (2.2-7.44) 7,4 (6,2-11,1)
Table 7: Hazard ratio, medians of overall survival and p-values of the two groups of patients established by the G 
and GC models
Model Risk Group HR (CI 95%) p-value Median PFS 
(months)
G-model
Low-risk 1
0,001
NR
High-risk 3.29 (1.57-6.91) 14,9 (9,9-44,8)
GC-model
Low-risk 1
<0,001
44,8 (33,3-NR)
High-risk 3.43 (1.62-7.26) 16,8 (9,9-37,4)
variables. Both had good accuracy in the first six months, 
whereas the GC-model remained accurate over time.
These findings should be evaluated in larger 
independent series in order to develop a routine clinical 
test to predict the benefit of bevacizumab in mBC patients.
MATERIALS AND METHODS
Patient selection and tumor sample collection
The study was approved by our institutional 
Ethics Committee. Patients with a diagnosis of HER2-
negative mBC between 2007 and 2011 and treated with 
bevacizumab and paclitaxel were identified from local 
records. The schedule consisted of bevacizumab 10 mg/
m2 days 1 and 15 plus weekly paclitaxel 80 mg/2 days 1, 
8 and 15, on a 28-day cycle. REMARK criteria were used 
to help in patient selection [21].
Seventy eight patients fulfilled the inclusion criteria. 
Six of them were excluded due to the absence of primary 
tumor biopsy, and another 12 because of poor quality 
material. The study included the primary tumor from 
60 patients. All of them had a minimum follow-up of 
18 months since the beginning of the treatment (unless 
progression and/or death due to mBC occurred before). 
Patients with an early withdrawal due to toxicity were not 
included.
The variable selected to generate a gene signature 
was progression-free survival, defined as the time from the 
first administration of bevacizumab-paclitaxel treatment to 
the first evidence of relapse, death or last record available 
dates. Other outcome variables, such as response to 
treatment and overall survival, were also evaluated but 
were not used to develop the molecular signature.
Gene expression analysis
RNA purification from FFPE samples
Sixty archival FFPE cases were evaluated by two 
breast cancer expert pathologists. Regions of invasive 
carcinoma were confirmed, and different areas with more 
than 80% of malignant epithelial cells were selected. Four 
to eight μm sections were used for total RNA isolation, 
with MasterPure RNA Purification Kit (EPICENTRE 
Biotechnologies, Madison, WI, USA) according to the 
manufacturer´s instructions with minor modifications. 
RNA concentrations and quality were measured using 
a Nanodrop 1000A spectrophotometer (Nanodrop 
Technologies, Wilmington, DE, USA).
Real-Time Quantification of Gene Expression
One μg of total RNA was used for cDNA synthesis 
with the High Capacity Archive cDNA Reverse 
Transcription kit (Applied Biosystems, Foster City, CA, 
USA), and performed in an Applied Biosystems 7900 
thermal cycler for 10 min at 25°C, 120 min at 37°C, and 
then held at 4°C.
The RT obtained products were amplified using 
a Real Time Ready Custom panel 384 (Hoffmann-La 
Oncotarget24224www.impactjournals.com/oncotarget
Roche, Basel, Switzerland). This platform enables the 
quantitation of 168 genes (Supplementary Table) plus 
19 housekeeping (HK) genes and 5 internal controls per 
sample. The reactions were performed on the LightCycler® 
480 as follows: an initial step at 95°C for 10 min, 45 
amplification cycles with 10s at 95°C, 30s at 60°C, and 1s 
at 72°C, and a final cooling step at 40°C for 30s.
Data processing
168 candidate genes were selected from the 
literature as related with the angiogenic process and other 
progression and resistance mechanisms, such as EMT or 
inflammation.
Nineteen housekeeping (HK) genes were also 
included in the study (Supplementary Table 1). Twelve of 
Figure 2: Time-dependent ROC curves for the three models (GC, G and C). a. At 6 months, b. At 24 months, c. AUC evolution 
for each model over time, d. AUC values for each model at four specific time points
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them were selected by GeNorm software [22] and used for 
the normalization factor applied to the raw data to get the 
relative expression value by the DDCt.
Statistical analysis
Univariate Cox regression models were fitted 
to evaluate the association between continuous RNA 
expression values and clinical covariates with survival.
The prediction models were built with penalized 
multivariate Cox regression proportional hazards 
modelling using L1-penalized (Lasso). A cross-validated 
(CV) risk score was calculated by leave-one-out cross-
validation (LOOCV) for each model [6, 7]. Patients were 
classified into high- and low-risk groups, based on the 
median value of the cross-validated risk score, and cross-
validated Kaplan-Meier curves (CV KM) were estimated. 
A log-rank statistic was computed for the CV KM plots 
and the statistical significance was evaluated based on 
the permutation distribution of the cross-validated log-
rank-statistic, repeating the whole LOOCV process 
with randomly permuted survival times and censoring 
indicators. Cross-validated time dependent receiver 
operating characteristics (ROC) curves were computed 
using the cross-validated risk scores. The area under the 
curve (AUC) values calculated from the CV ROC curves 
were used as measure of predictive accuracy of the models 
[8]. All statistical analyses were performed using R 
software (version 3.1.1) and the analysis was conducted by 
the penalized and survival ROC packages in R software.
Inmunohistochemistry analysis
Genes found to be related to PFS in the multivariate 
analysis were further analyzed by tissue microarray. 
Representative areas of the tumors were selected on 
hematoxylin and eosin-stained sections and marked on 
individual paraffin blocks by an expert pathologist in the 
field. Two tissue cores (1 mm in diameter) were obtained 
from each specimen. The tissue cores were arrayed into a 
receptor paraffin block using a TMA workstation (Beecher 
Instruments, Silver Spring, MD, USA), as described 
previously [23]. A hematoxylin and eosin-stained section 
of the array was reviewed to confirm the presence of 
Figure 3: Representative Inmunohistochemistry for REL, SLC39A6, NOTCH3, FN1 and DDIT4.
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morphologically representative areas of the original 
lesions.
Immunohistochemistry (IHC) was performed as 
described previously [24] on 4um sections of the TMAs, 
obtained by a semiautomated microtome HM3508 
(Microm). Briefly, the tissue sections were deparaffinized 
and rehydrated in water, after which antigen retrieval 
was carried out in a DAKO PT Link in citrate buffer 
(pH=6). Endogenous peroxidase and nonspecific antibody 
reactivity was blocked with peroxidase blocking reagent 
(Dako, Glostrup, Denmark) at room temperature for 
15 min.
The sections were then incubated for 60 min with 
the following antibodies: rabbit monoclonal cMET (SP44, 
#790-4430, Hoffmann-La Roche Ltd, Basel, Switzerland) 
and cREL (EPR2258, #ab108299, Abcam, Cambridge, 
UK); rabbit polyclonal: FN1 (#A0245, Dako, Glostrup, 
Denmark), SLC39A6 (#ab61307), DDIT4 (#ab63059), 
and NOTCH3 (#ab60087), all these last from Abcam 
(Cambridge, UK). Detection was performed with Envision 
Plus Detection System (Dako, Glostrup, Denmark).
Cytoplasmic staining for cREL and SLC39A6, 
as well as nuclear and cytoplasmic staining for DDIT4 
was classified as negative, focal or diffuse. NOTCH3 
presence was diffuse when present, so we evaluated 
absence or weak/strong staining. Stromal FN1 staining 
observed in the stromal component was also evaluated. 
The pathologists performing the immunohistochemistry 
analysis were blinded for patient´s outcome.
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